胃がん治療薬の世界市場レポート 2024年

胃がん治療薬の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には11.9%の年間複合成長率（CAGR）で69億2,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、胃がんの発生率の増加、医薬品の強力なパイプライン、医薬品開発のための買収と提携の急増、医療費の増加、新興経済国の高い潜在力、高齢者人口の増加、生物製剤開発の促進を目的とした改訂されたFDA規制。予測期間中に予想される主要動向には、製品ポートフォリオを拡大するための戦略的提携や協定、新薬の開発を促進するための他の企業や政府機関とのパートナーシップ、胃がん治療薬開発のためのパイプライン研究の数の増加、AIソリューションへの投資などが含まれます。研究開発コストの削減、収益と市場シェアを拡大するための次世代生物製剤の開発、新薬開発や胃がん治療の結果向上のためのCRISPR-Cas9技術の使用などが挙げられます。

肥満の有病率の上昇と喫煙者の増加は、胃がんの発生率の増加に寄与しています。喫煙と不健康な食事は胃がんの危険因子として特定されています。米国がん研究所の2020年の推定によると、約2万7,600例の胃がんが診断されると予測されており、その内訳は男性が1万6,980例、女性が1万620例となっています。胃がん症例数の増加により、胃がん治療薬市場の拡大が促進されると予想されます。

世界の高齢化人口の拡大は、胃がん治療薬市場の将来の成長を促進すると予想されます。高齢化人口は、平均余命の延長と出生率の低下により、65歳以上の人口がかなりの割合で占められることが特徴です。この人口動態の変化により、手術や化学療法などの特定のがん治療に対する耐性が限られている高齢患者の特有のニーズや耐性に対応するために、薬物を含む個別の治療選択肢が必要となります。たとえば、2021年8月にThe Printが報じたように、インド国家統計局の高齢者統計によると、インドの高齢者人口（60歳以上）は2021年の1億3,800万人から41％増加し、2031年までに1億9,400万人に達すると予想されています。 したがって、胃がん治療薬市場は、高齢者人口の拡大により成長する傾向にあります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の胃がん治療薬市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の胃がん治療薬市場規模実績と成長、2018～2023年
• 世界の胃がん治療薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の胃がん治療薬市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 塩酸ドキソルビシン
• スニチニブ
• ドセタキセル
• マイトマイシン
• フルオロウラシル
• イマチニブ
• トラスツズマブ
• 世界の胃がん治療薬市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 経口
• 非経口
• 世界の胃がん治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• クリニック
• その他

第7章 地域と国の分析

• 世界の胃がん治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の胃がん治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃がん治療薬市場の競合情勢
• 胃がん治療薬市場企業プロファイル
  • F. Hoffmann-La Roche
  • Eli Lilly and Company
  • Otsuka Pharmaceutical
  • Jiangsu HengRui Medicine
  • Biocon

第31章 その他の大手と革新的な企業

• Sanofi
• PV Pharma Healthcare（インド）
• Roche India
• Novartis Oncology
• Arlak Biotech（インド）
• Healthkind labs Pvt. Ltd.
• SwisscheM Healthcare Pvt.Ltd
• Apikos Pharma
• Kolaz biotech.
• CStone Pharma（中国）
• CARsgen Therapeutics（中国）
• JW Therapeutics（中国）
• BeiGene（中国）
• Takeda Pharmaceuticals（日本）
• Astellas Pharma Inc（日本）

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Gastric cancer drugs encompass anti-cancer medications administered either orally in the form of pills or through injection into a vein via an IV line or central venous catheter. This form of treatment proves effective for cancers that have metastasized to organs beyond their origin, as these medications travel through the bloodstream, reaching all parts of the body.

The primary types of gastric cancer drugs include doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. Sunitinib functions as both a chemotherapeutic agent and a receptor tyrosine kinase inhibitor, employed in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumors (GIST). These drugs are administered via oral and parenteral routes and find application in hospitals, clinics, and other healthcare settings.

The gastric cancer drugs market research report is one of a series of new reports from The Business Research Company that provides gastric cancer drugs market statistics, including gastric cancer drugs industry global market size, regional shares, competitors with a gastric cancer drugs market share, detailed gastric cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer drugs industry. This gastric cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric cancer drugs market size has grown rapidly in recent years. It will grow from $3.91 billion in 2023 to $4.41 billion in 2024 at a compound annual growth rate (CAGR) of 12.8%. The growth observed in the historical period can be ascribed to the rise in pharmaceutical research and development (R&D) expenditure, augmented healthcare spending, robust economic growth in emerging markets, and the swift expansion of the elderly population.

The gastric cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $6.92 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be ascribed to the increase in the incidence rate of gastric cancer, a robust pipeline of drugs, a surge in acquisitions and partnerships for drug development, a rise in healthcare expenditure, high potential in emerging economies, a growing geriatric population, and revised FDA regulations aimed at facilitating biologics drug development. Major trends expected in the forecast period include strategic collaborations and agreements to expand product portfolios, partnerships with other companies or government bodies to expedite the development of new drugs, an increase in the number of pipeline studies for the development of gastric cancer drugs, investments in AI solutions to reduce R&D costs, the development of next-generation biologics to enhance revenue and market share, and the use of CRISPR-Cas9 technology in new drug developments or for improved results in gastric cancer treatments.

The rising prevalence of obesity and an increasing number of smokers have contributed to a higher incidence of gastric cancer. Tobacco consumption and an unhealthy diet are identified as risk factors for stomach cancer. According to the American Institute for Cancer Research's 2020 estimates, approximately 27,600 cases of stomach cancer were projected to be diagnosed, with 16,980 in men and 10,620 in women. The growing number of gastric cancer cases is expected to fuel the expansion of the gastric cancer drugs market.

The expanding global aging population is anticipated to drive the future growth of the gastric cancer drug market. An aging population is characterized by a significant proportion of individuals aged 65 and above, resulting from increased life expectancy and reduced birth rates. This demographic shift necessitates tailored treatment options, including drugs, to accommodate the specific needs and tolerances of elderly patients who may have limited tolerance for certain cancer treatments such as surgery or chemotherapy. For example, as reported by The Print in August 2021, India's elderly population (aged 60 and above) is expected to reach 194 million by 2031, reflecting a 41% increase from 138 million in 2021, according to the National Statistical Office's Elderly in India 2021. Consequently, the gastric cancer drug market is poised for growth due to the expanding elderly population.

Numerous companies are employing combination therapies as a strategy to combat gastric cancer effectively. Combination therapies involve the simultaneous use of two or more drugs to treat a single disease, enhancing patient care. For instance, in January 2021, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, announced the FDA approval of Enhertu (trastuzumab deruxtecan) in the US for treating adult patients with locally progressed or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinomas. This therapy, combining trastuzumab with a fluoropyrimidine- and platinum-based chemotherapy, is administered to individuals facing advanced gastric cancer or GEJ adenocarcinoma who have previously undergone a trastuzumab-based regimen.

Major companies in the gastric cancer drugs market are introducing innovative medications such as Nivolumab (Opdivo) to maintain a competitive edge. Nivolumab is an immune checkpoint inhibitor belonging to the Programd death receptor-1 (PD-1) blockers class, used in cancer therapy. The incorporation of immune checkpoint inhibitors in gastric cancer treatment aligns with the broader effort to develop more targeted and effective therapies for the disease. For example, in April 2021, Bristol-Myers Squibb Company, a US-based biopharmaceutical company, received FDA approval for Opdivo (nivolumab) injection for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, irrespective of PD-L1 expression status.

In March 2021, Amgen Inc., a US-based biopharmaceutical company, completed the acquisition of Five Prime Therapeutics, Inc. for $1.9 billion. This strategic move by Amgen enhances its oncology product portfolio, assets for gastric cancer treatment, monoclonal antibody manufacturing capabilities, and drug development capabilities, particularly for biological drugs targeting advanced gastric or gastroesophageal junction (GEJ) cancer. Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing immuno-oncology protein therapeutics for cancer treatment.

Major companies operating in the gastric cancer drugs market report are F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca PLC, GlaxoSmithKline PLC, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratorios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, GSK, Gilead Sciences, BMS, Ascedis Health

North America was the largest region in the gastric cancer drugs market in 2023. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The gastric cancer drugs market consists of sales of cyramza, docetaxel, and doxorubicin hydrochloride. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastric Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastric cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastric cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastric cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Imatinib; Trastuzumab; Other Types
• 2) By Route of Administration: Oral; Parenteral
• 3) By End User: Hospitals; Clinics; Cancer Specialty Centers
• Companies Mentioned: F. Hoffmann-La Roche; Eli Lilly and Company; Otsuka Pharmaceutical; Jiangsu HengRui Medicine; Biocon
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastric Cancer Drugs Market Characteristics

3. Gastric Cancer Drugs Market Trends And Strategies

4. Gastric Cancer Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Gastric Cancer Drugs Market Size and Growth

• 5.1. Global Gastric Cancer Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Gastric Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Gastric Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gastric Cancer Drugs Market Segmentation

• 6.1. Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Doxorubicin Hydrochloride
• Sunitinib
• Docetaxel
• Mitomycin
• Fluorouracil
• Imatinib
• Trastuzumab
• 6.2. Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oral
• Parenteral
• 6.3. Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Other End-users

7. Gastric Cancer Drugs Market Regional And Country Analysis

• 7.1. Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gastric Cancer Drugs Market

• 8.1. Asia-Pacific Gastric Cancer Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gastric Cancer Drugs Market

• 9.1. China Gastric Cancer Drugs Market Overview
• 9.2. China Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gastric Cancer Drugs Market

• 10.1. India Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gastric Cancer Drugs Market

• 11.1. Japan Gastric Cancer Drugs Market Overview
• 11.2. Japan Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gastric Cancer Drugs Market

• 12.1. Australia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gastric Cancer Drugs Market

• 13.1. Indonesia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gastric Cancer Drugs Market

• 14.1. South Korea Gastric Cancer Drugs Market Overview
• 14.2. South Korea Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gastric Cancer Drugs Market

• 15.1. Western Europe Gastric Cancer Drugs Market Overview
• 15.2. Western Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gastric Cancer Drugs Market

• 16.1. UK Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gastric Cancer Drugs Market

• 17.1. Germany Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gastric Cancer Drugs Market

• 18.1. France Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gastric Cancer Drugs Market

• 19.1. Italy Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gastric Cancer Drugs Market

• 20.1. Spain Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gastric Cancer Drugs Market

• 21.1. Eastern Europe Gastric Cancer Drugs Market Overview
• 21.2. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gastric Cancer Drugs Market

• 22.1. Russia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gastric Cancer Drugs Market

• 23.1. North America Gastric Cancer Drugs Market Overview
• 23.2. North America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gastric Cancer Drugs Market

• 24.1. USA Gastric Cancer Drugs Market Overview
• 24.2. USA Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gastric Cancer Drugs Market

• 25.1. Canada Gastric Cancer Drugs Market Overview
• 25.2. Canada Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gastric Cancer Drugs Market

• 26.1. South America Gastric Cancer Drugs Market Overview
• 26.2. South America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gastric Cancer Drugs Market

• 27.1. Brazil Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gastric Cancer Drugs Market

• 28.1. Middle East Gastric Cancer Drugs Market Overview
• 28.2. Middle East Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gastric Cancer Drugs Market

• 29.1. Africa Gastric Cancer Drugs Market Overview
• 29.2. Africa Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gastric Cancer Drugs Market Competitive Landscape And Company Profiles

• 30.1. Gastric Cancer Drugs Market Competitive Landscape
• 30.2. Gastric Cancer Drugs Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Eli Lilly and Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Otsuka Pharmaceutical
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Jiangsu HengRui Medicine
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Biocon
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Gastric Cancer Drugs Market Other Major And Innovative Companies

• 31.1. Sanofi
• 31.2. PV Pharma Healthcare (India)
• 31.3. Roche India
• 31.4. Novartis Oncology
• 31.5. Arlak Biotech (India)
• 31.6. Healthkind labs Pvt. Ltd.
• 31.7. SwisscheM Healthcare Pvt.Ltd
• 31.8. Apikos Pharma
• 31.9. Kolaz biotech.
• 31.10. CStone Pharma (China)
• 31.11. CARsgen Therapeutics (China)
• 31.12. JW Therapeutics (China)
• 31.13. BeiGene(China)
• 31.14. Takeda Pharmaceuticals (Japan)
• 31.15. Astellas Pharma Inc (Japan)

32. Global Gastric Cancer Drugs Market Competitive Benchmarking

33. Global Gastric Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gastric Cancer Drugs Market

35. Gastric Cancer Drugs Market Future Outlook and Potential Analysis

• 35.1 Gastric Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Gastric Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Gastric Cancer Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer